4 assets in Autoimmune Lymphoproliferative Syndrome

Therapeutic assets addressing Autoimmune Lymphoproliferative Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Alemtuzumab Autoimmune Lymphoproliferative Syndrome	Washington University School of Medicine	P2	CCC (53)
Fludarabine Autoimmune Lymphoproliferative Syndrome	Washington University School of Medicine	P2	CCC (53)
Melphalan Autoimmune Lymphoproliferative Syndrome	Washington University School of Medicine	P2	CCC (53)
Thiotepa Autoimmune Lymphoproliferative Syndrome	Washington University School of Medicine	P2	CCC (53)